Last reviewed · How we verify

NCT05460026

Effects Of Power Ball Exercises In Addition To Routine Physical Therapy In Patients With Carpal Tunnel Syndrome

Completed NA Last updated 6 April 2023
What this trial tests

NA trial testing Routine Physical Therapy in Carpal Tunnel Syndrome in 86 participants. Completed in 23 December 2022.

Timeline
23 December 2021
Primary endpoint
23 May 2022
23 December 2022

Quick facts

Lead sponsorUniversity of Lahore
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment86
Start date23 December 2021
Primary completion23 May 2022
Estimated completion23 December 2022
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

University of Lahore

Who can join

Adults 45 to 60, any sex, with Carpal Tunnel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose for doing this study is to determine that whether use of Power Ball in form of resistance training will be effective in increasing grip strength in carpel tunnel syndrome patient and possible benefits of the regime as effective means of rehabilitation for wrist and hand injuries. Moreover for increasing grip strength it can be used as an adjunct for physical therapy treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Routine Physical Therapy

Trials testing the same drug.

Other recruiting trials for Carpal Tunnel Syndrome

Currently open trials in the same condition.

Other University of Lahore trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05460026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing